GENZYME THERAPEUTICS LTD
Founded in 1981, Genzyme is now
one of the world's largest and most established
biotechnology companies. With more than 25 major
products and services marketed in over 60 countries,
Genzyme is a global leader in the effort to develop and
apply the most advanced capabilities in biotechnology, in
order to address a range of unmet medical needs.
With corporate headquarters in Cambridge, MA, USA,
Genzyme has approximately 4600 employees working in 40
countries throughout the world. The European headquarters
are in Naarden, The Netherlands, and the UK headquarters
covering the whole of the British Isles are now based in
Oxford.
Genzyme-sponsored R&D has led to the introduction of
new treatments for many serious health problems, from rare
and debilitating genetic diseases to renal disease,
orthopaedic injuries, transplantation and thyroid cancer. One
of Genzyme's most significant successes is Thyrogen
(thyrotropin alfa), which contains a highly purified
recombinant form of human TSH. It can be used to
eliminate the devastating and painful symptoms of thyroid
hormone withdrawal that patients may experience when
they are tested for a recurrence of thyroid cancer. Thyrogen
will also lead to more accurate thyroglobulin measurements
on thyroid hormone suppression.
Genzyme has a commitment to improving the lives of
patients and supporting the work of doctors and other
healthcare providers.
Genzyme Therapeutics Ltd, 4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford OX4 2SU, UK
Tel:
01865-405200
http://www.genzyme.com